Business Description
Lexicon Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US5288723027
Share Class Description:
LXRX: Ordinary SharesDescription
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.55 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | -0.51 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -8.37 | |||||
| Beneish M-Score | 5.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -71.5 | |||||
| 3-Year EBITDA Growth Rate | -25.8 | |||||
| 3-Year EPS without NRI Growth Rate | 22.5 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| 3-Year Book Growth Rate | -29.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 22.08 | |||||
| Future 3-5Y Total Revenue Growth Rate | 292.02 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.91 | |||||
| 9-Day RSI | 24.75 | |||||
| 14-Day RSI | 26.83 | |||||
| 6-1 Month Momentum % | 23.78 | |||||
| 12-1 Month Momentum % | 82.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.45 | |||||
| Quick Ratio | 7.43 | |||||
| Cash Ratio | 7.17 | |||||
| Days Inventory | 529.57 | |||||
| Days Sales Outstanding | 116.84 | |||||
| Days Payable | 13155.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.1 | |||||
| Shareholder Yield % | -7.35 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.54 | |||||
| Operating Margin % | -4037.43 | |||||
| Net Margin % | -4138.33 | |||||
| FCF Margin % | -3974.7 | |||||
| ROE % | -115.11 | |||||
| ROA % | -66.89 | |||||
| ROIC % | -333.79 | |||||
| ROC (Joel Greenblatt) % | -2705.74 | |||||
| ROCE % | -67.94 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 44.65 | |||||
| PB Ratio | 1.63 | |||||
| Price-to-Tangible-Book | 2.17 | |||||
| EV-to-EBIT | -0.67 | |||||
| EV-to-Forward-EBIT | -1.41 | |||||
| EV-to-EBITDA | -0.67 | |||||
| EV-to-Forward-EBITDA | -1.41 | |||||
| EV-to-Revenue | 25.5 | |||||
| EV-to-Forward-Revenue | 18.78 | |||||
| EV-to-FCF | -0.64 | |||||
| Price-to-Net-Current-Asset-Value | 2.3 | |||||
| Price-to-Net-Cash | 2.51 | |||||
| Earnings Yield (Greenblatt) % | -149.25 | |||||
| FCF Yield % | -71.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LXRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lexicon Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.229 | ||
| EPS (TTM) ($) | -0.75 | ||
| Beta | 1.24 | ||
| Volatility % | 107.87 | ||
| 14-Day RSI | 26.83 | ||
| 14-Day ATR ($) | 0.102047 | ||
| 20-Day SMA ($) | 1.001775 | ||
| 12-1 Month Momentum % | 82.88 | ||
| 52-Week Range ($) | 0.73 - 3.73 | ||
| Shares Outstanding (Mil) | 361.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lexicon Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lexicon Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lexicon Pharmaceuticals Inc Frequently Asked Questions
What is Lexicon Pharmaceuticals Inc(LXRX)'s stock price today?
The current price of LXRX is $0.80. The 52 week high of LXRX is $3.73 and 52 week low is $0.73.
When is next earnings date of Lexicon Pharmaceuticals Inc(LXRX)?
The next earnings date of Lexicon Pharmaceuticals Inc(LXRX) is 2025-02-12 Est..
Does Lexicon Pharmaceuticals Inc(LXRX) pay dividends? If so, how much?
Lexicon Pharmaceuticals Inc(LXRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers